CD274 and cancer: Recently, increasing evidence has emerged in support of the hypothesis that the anti-tumor mechanisms of anti-PD-L1 Ab in cancer immunotherapy come mainly through its targeting of PD-L1-expressed antigen-presenting cells, such as DCs and macrophages [10,23].